PafosPharma, LLC, a privately held biopharmacetical company is dedicated to developing novel medications for therapeutic indications related to the endocannabinoid biochemical system. Located in Burlington, MA, Pafos is based on 35 years of cannabinoid research by Professor Alexandros Makriyannis - George D. Behrakis Endowed Chair, Director of the Center for Drug Discovery, Northeastern University. PafosPharma has substantial drug development assets that include (i) proprietary understanding of all the major endocannabinoid pathway(s), (ii) validated targets for therapeutic drug development, and (iii) a library of potent and highly selective cannabinergic compounds some of which are currently in preclinical testing. The Company owns various families of pharmacologically active compounds being utilized as targets for drug discovery for conditinsranging from Irritable Bowel Syndrome, through addiction, PTSD and Neuropathic Pain.
